WO 2005/001053 PCT/US2004/018451

1. A method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonists to the mammal.

- 2. The method of claim 1, wherein the method is used to treat a tumor growth or angiogenesis in the mammal.
- 3. The method of claim 1 or 2, wherein the RTK is Epidermal Growth Factor Receptor (EGFR).
- 4. The method of claim 3, wherein the extracellular RTK antagonist is cetuximab, ABX-EGF, EMD 72000, h-R3, or Y10.
- 5. The method of claim 3, wherein the intracellular RTK antagonist is ZD1939 or OSI-774.
  - 6. The method of claim 1 or 2, wherein the RTK is HER2 receptor.
- 7. The method of claim 6, wherein the extracellular RTK antagonist is trastuzumab.
- 8. The method of claim 1 or 2, wherein the RTK is Vascular Endothelial Growth Factor Receptor (VEGFR).
- 9. The method of claim 8, wherein the extracellular RTK antagonist is bevacizumab.
- 10. The method of claim 1 or 2, wherein the intracellular RTK antagonist inhibits ras protein or a ras-raf modulator.
- 11. The method of any one of claims 1-10, wherein the method further comprises administrating an antineoplastic agent.

WO 2005/001053 PCT/US2004/018451

12. A pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist.

- 13. The pharmaceutical composition of claim 12, wherein the RTK is Epidermal Growth Factor Receptor (EGFR).
- 14. The pharmaceutical composition of claim 13, wherein the extracellular RTK antagonist is cetuximab, ABX-EGF, EMD 72000, h-R3, or Y10.
- 15. The pharmaceutical composition of claim 13 or 14, wherein the intracellular RTK antagonist is ZD1939 or OSI-774.
- 16. The pharmaceutical composition of any claim 12, wherein the RTK is HER2 receptor.
- 17. The pharmaceutical composition of claim 16, wherein the extracellular RTK antagonist is trastuzumab.
- 18. The pharmaceutical composition of claim 12, wherein the RTK is Vascular Endothelial Growth Factor Receptor (VEGFR).
- 19. The pharmaceutical composition of claim 18, wherein the extracellular RTK antagonist is bevacizumab.
- 20. The pharmaceutical composition of claim 12, wherein the intracellular RTK antagonist inhibits ras protein or a ras-raf modulator.
- 21. The pharmaceutical composition of any one of claims 12-20, wherein the pharmaceutical composition further comprises an antineoplastic agent.